Hims & Hers Health (HIMS) Shares Tumble on Wegovy Shortage Resolution
Impact:
Shares of Hims & Hers Health (NYSE: HIMS) plunged 24% following the Food and Drug Administration's (FDA) announcement that the weight-loss drug shortage has ended.
Market Volatility:
Hims & Hers Health's stock has experienced significant volatility, with 73 moves exceeding 5%. This recent drop is particularly noteworthy and suggests a substantial market reaction to the news.
Acquisition and Growth Potential:
Two days prior to the FDA announcement, Hims & Hers Health surged 24.8% on the news of its acquisition of Sigmund (Trybe Labs), expanding its platform to include home lab testing. This capability enhances subscriber disease detection and treatment recommendations through AI initiatives like MedMatch.
Historical Performance:
Despite today's drop, Hims & Hers Health remains up 98.9% year-over-year and 27% below its February 2025 high of $68.74. A $1,000 investment five years ago is now worth approximately $4,964.
Future Outlook:
Generative AI-leveraging enterprise software stocks may present significant growth opportunities similar to the "Gorillas of the future" described in the classic investment book, "Gorilla Game."